Impact of hypertension on stroke

Current Atherosclerosis Reports

Volumn 13, Issue 4, 2011, Pages 298-305

  Dubow, Jordan ^a   Fink, Matthew E ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Brain aneurysms; Hypertension; Intracerebral hemorrhage; Stroke; Subarachnoid hemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; LABETALOL; LISINOPRIL; LOSARTAN; NICARDIPINE; NIMODIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TINZAPARIN;

ANGIOGENESIS; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG DOSE TITRATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; NEUROPROTECTION; NONHUMAN; PATHOLOGY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STROKE; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; VASOSPASM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; HUMANS; HYPERTENSION; INTRACRANIAL HEMORRHAGE, HYPERTENSIVE; PRACTICE GUIDELINES AS TOPIC; STROKE; SUBARACHNOID HEMORRHAGE;

EID: 80052574445     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0187-y     Document Type: Article

References (57)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72.
2. Gillepsie C, Kuklina EV, Briss PA et al. Vital signs: prevalence, treatment, and control of hypertension-United States, 1999-2002 and 2005-2008. Morbidity and Mortality Weekly Report. 2011;60 (4):102-8. This report contains the most recent population-based data regarding the prevalence and treatment of hypertension in the United States. It demonstrates how treatment has improved over the past several decades.
3. Rosamund W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Subcommittee. Circulation. 2008;117(4): e25-146.
4. Carandang R, Seshadri S, Beuser A, et al. Trends in incidence, lifetime risk severity and 30-day mortality of stroke over the last 50 years. JAMA. 2006;296(24):2939-46.
5. Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA. 1970;214:301-10.
6. Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981;245:1225-9.
7. Johansson BB. Hypertension mechanisms causing stroke. Clin Exp Pharmacol Physiol. 1999;7:563-5.
8. Fisher C. Pathological observations in hypertensive cerebral hemorrhage. J Neuropath Exp Neurol. 1971;30:536-50.
9. Heistad DD, Mayhan WG, Baumbach GL. Impaired dilation of cerebral arterioles in chronic hypertension. Blood Vessels. 1990;27:258-62.
10. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension. 12:89-95.
11. Rost NS, Rahman RM, Biffi A et al. White matter hyperintensity volume is increased in small vessel stroke subtypes. Neurology. 2010;75:1670-77. White matter hyperintensities, or leukoaraiosis, as diagnosed on MRI, have been noted as a risk factor for subsequent small vessel strokes as well as intracerebral hemorrhage, and have also been linked to chronic hypertension.
12. O'Sullivan M. Leukoaraiosis. Pract Neurol. 2008;8:26-38.
13. Berenstein A, Lasjaunias P, Ter Brugge KG. Aneurysmal vasculopathy: segmental vulnerability. In: Surgical neuroangiography. Berlin: Spring-Verlag; 2004. 375-80.
14. Ruland SD. Lifestyle modification, antihypertensives, and cholesterol-lowering medication for primary and secondary stroke prevention. Continuum. 11;4:47-60.
15. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens. 1996;14 Suppl 6:S39-46.
16. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure-lowering regimen amont 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:1033-41.
17. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
18. Dahlof B, Devereuz RB, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
19. ALHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA. 2002;288:2981-97.
20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA. 1991;265:3255-64.
21. Yusuf S, Diener H-C, Sacco RL, for the Prevention Regimen for Effictively avoiding Second Strokes (PRoFESS) study group, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225-37.
22. Poulter NR, Wedel H, Dahlof B, for the ASCOT Investigators, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outomces Trial-Blod pressure lowering Arm (ASCOTBPLA). Lancet. 2005;366:907-13.
23. Staussen JA, Thijs L, Gasowski J, et al. Dihydropyridine calcium channel blockers for antihypertensive treatment in older patients- evidence from the Systolic Hypertension in Europe Trial. S Afr Med J. 2001;12:1060-8.
24. Black HR, Elliot WJ, Grandits G, et al. Results of the controlled Onset Verapamil Investigation of Cardiovascular Endpoints by geographic region (CONVINCE). J Hypertens. 2005;23(5):1099-106.
25. Lindolm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-53.
26. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as firstline agents: a network meta-analysis. JAMA. 2003;289:2534-44.
27. Wright JM, Musini VM. First line agents for hypertension. Cochrane Database Syst Rev. 2009:CD001841.
28. Adams H, Del Zoppo G, Alberts M, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular and Interventional Radiology and Intervention Council and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-711.
29. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569-81.
30. Leonardi-Bee J, Bath PM, Phillips SJ, FRCP for the IST Collaborative Group, et al. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315-20.
31. The National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.
32. Geeganage C, Tracy M, England T, et al. for TIAST Investigators. Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke. Stroke. 2011;42:491-93. The TIAST trial showed that early death and neurologic deterioration, as well as recurrent stroke, were independently associated with baseline high systolic BP, mean arterial BP, pulse pressure, and blood pressure variability.
33. Ahmed J, Nassman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute ischemic stroke. Stroke. 2000;31:1250.
34. Schrader J, Luders S, Kulschewski A, on behlaf of the ACCESS Study Group, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003;34:1699-703.
35. Sandset EC, Bath PW, Boysen G, et al. on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomized, placebocontrolled, double-blind trial. Lancet. 2011;371:741-50. In this trial, candesartan, compared with placebo, resulted in a lower BP in the acute setting of ischemic stroke, but this did not result in reduced mortality, or recurrent stroke risk.
36. Shin HK, Nishimura M, Jones PB, et al. Mild induced hypertension improves blood flow and oxygen metabolism in transient focal cerebral ischemia.
37. Wise G, Sutter R, Burhkolder J. The treatment of brain ischemia with vasopressor drugs. Stroke. 1972;3:135-40.
38. Hillis AE, Ulatowski JA, Barker PB, et al. A pilot randomized trial of induced blod pressure elevation: effects of function and focal perfusion in acute and subacute stroke. Cerebrovasc Dis. 2003;16:236-46.
39. Marzan AS, Hungerbuhler JH, Studer A, et al. Feasibility and safety of norepinephrine induced arterial hypertension in acute ischemic stroke. Neurology. 2004;62:1193-5.
40. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005;352:1305-16.
41. Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontenous intracerebral hemorrhage. Stroke. 1986;17:1078-83.
42. Brott T, Broderick J, Korthari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
43. Olson JD. Mechanisms of hemeostasis: effect of intracerebral hemorrhage. Stroke. 1993;24:1109-14.
44. Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral hemorrhage trial (INTERACT): a randomized pilot trial. Lancet Neurol. 2008;7:391-9.
45. ATACH Investigators. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH). Crit Care Med. 2010;38:637-48. This trial compared BP targets in acute intracerebral hemorrhage but did not demonstrate any clinical differences in outcomes between the groups.
46. Zhang Y, Reilly KH, Tong W, et al. Blood pressure and clinical outcomes among patients with acute stroke in Inner Mongolia, China. J Hypertens. 2008;26:1446-52.
47. Wilmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systemic review. Hypertension. 2004;43:18-24.
48. Morgenstern LB, Hemphill JC, Anderson C, on behalf of the American Heart Association Stroke Council and Council on Cardiovascular Nursing, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108-29.
49. Teunissen LL, Rinkel GJ, Algra A, et al. Risk factors for subarachnoid hemorrhage-a systemic review. Stroke. 1996;27:544-59.
50. Ingall TJ, Whisnant JP, Wiebers DO, et al. Has there been a decline in subarachnoid hemorrhage mortality? Stroke. 1989;20:718-24.
51. Manno EM. Subarachnoid hemorrhage. Neurol Clin N Am. 2004;22:347-66.
52. Ohkuma H, Tsuratani H, Suzuki S. Incidence and significance of early aneursysmal rebleeding before neurosurgical or neurological management. Stroke. 2001;32:1176-80.
53. Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 1990;92:111-7.
54. Bederson JB, Sander-Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage a statement for healthcare professionals from a special Writing Group of the Stroke Council, American Heart Association. Stroke. 2009;40:994-1025. This is the most recent guideline from the AHA regarding the treatment of patients with aneurysmal subarachnoid hemorrhage and should be mandatory reading for all who care for such patients.
55. Matsuda M, Watanabe K, Saito A, et al. Circumstances, activities and events precipitating aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2007;16:25-9.
56. Anda T, Yonekura M, Baba H, et al. Factors affecting rapid growth of unruptured cerebral aneurysms during the acute stage of subarachnoid hemorrhage. Neurol Res. 2006;28:165-71.
57. Juvela S. Prehemorrhage risk factors for fatal intracranial aneurysm rupture. Stroke. 2003;34:1852-7.